Developer docs
API playgroundTry for free, no card

Search company profiles

Respira Therapeutics

Full company profile

uuid0003l2n

Namestring
Respira Therapeutics
Legal namestring
Respira Therapeutics Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Respira Therapeutics is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Palo Alto, California, developing next-generation inhaled therapies for cardiopulmonary diseases. The company is built around a proprietary drug-device platform combining the AOS™ (Axial Oscillating Sphere) Dry-Powder Inhaler, which uses four distinct dispersion elements to target the lung periphery, with advanced particle engineering formulations. Its lead candidate, RT234-PAH, is a first-in-class reformulation of vardenafil (a potent PDE5 inhibitor) as an inhalation powder intended for "as-needed" (PRN) use in patients with Pulmonary Arterial Hypertension (PAH). The company is also developing RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease (WHO Group 3.2). Respira has received FDA Orphan Drug designation for vardenafil in PAH and is pursuing approval via the 505(b)(2) regulatory pathway.

The company's business model is pre-commercial: Respira generates no product revenue and instead derives value from advancing clinical assets and from strategic partnership and licensing arrangements. As a 1-10 employee venture-backed entity (currently owned by Samsara BioCapital), the company selectively partners with pharmaceutical firms facing unique pulmonary delivery challenges. In September 2025, Respira entered an agreement with Gossamer Bio granting Gossamer an option to acquire the company and its inhaled vardenafil candidate. End-customers are PAH and ILD-PH patient populations (~30,000 each in the U.S.) in an estimated $8B global PAH treatment market; commercialization would route through standard pharmaceutical distribution and specialty pulmonary channels following FDA approval.

Leadership combines deep drug-device commercialization and inhaled delivery expertise, including CEO John Kollins (ex-Satsuma Pharmaceuticals CEO), Chairman William Fairey (former Actelion US President, ex-MyoKardia CCO), and board member Michael Riebe (former VP of Inhalation Product Development at AstraZeneca). Backed by Cottonwood Technology Fund, Sun Mountain Capital, Keiretsu Forum Northwest, and Samsara BioCapital, Respira has raised approximately $5.1M-$6.1M in disclosed equity financing through 2015 and is operating with Phase 2b VIPAH-PRN clinical data presented at ATS 2025 as its most recent substantive milestone.

Short descriptiontext

Respira Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class inhaled vardenafil therapies via its proprietary AOS™ Dry-Powder Inhaler for patients with Pulmonary Arterial Hypertension and ILD-associated Pulmonary Hypertension, currently pre-revenue and subject to a Gossamer Bio acquisition option.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled drug delivery, dry powder inhalers, pulmonary hypertension therapy, pharmaceutical drug development, vardenafil inhalation powder
Industry4 codes
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inhaled Pulmonary Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Expected to commercialize RT234-PAH and RT234-ILD PH upon FDA approval. Product is first-in-class inhaled therapy for PAH patients, contrasting with chronic treatment regimens of existing therapies.

respiratherapeutics.com
2Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Company selectively partners with pharmaceutical companies having unique pulmonary delivery challenges. Agreement with Gossamer Bio grants option to acquire Respira and its inhaled vardenafil product candidate.

respiratherapeutics.com
3Future Product Pipeline
TypeOne Time License
Description

Pipeline includes wholly owned development candidates with anticipation to launch additional product development programs. Focus on 505(b)(2) products that may improve standard of care.

respiratherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1RT234-PAH
Description

First-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue in pulmonary arterial hypertension (PAH) patients.

respiratherapeutics.com
+2 more records
Core offering1 text field

Respira Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug-device combination products for cardiopulmonary diseases. Its lead candidate RT234-PAH is a first-in-class inhaled vardenafil dry powder formulation delivered via the proprietary AOS™ Dry-Powder Inhaler (DPI), intended for as-needed (PRN) use in patients with Pulmonary Arterial Hypertension (PAH). The company also develops RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease and pursues 505(b)(2) regulatory pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2b clinical trial demonstrated acute improvement in exercise capacity and reduced dyspnea in PAH patients
+3 more records
Product overview1 text field

Respira Therapeutics is a clinical-stage biopharmaceutical company developing next-generation cardiopulmonary disease-targeted inhalation products. The company operates a platform combining its proprietary AOS™ dry-powder inhaler (DPI) device with advanced particle engineering-based inhaled drug formulations to enhance drug delivery to the lung periphery. The core product portfolio includes RT234-PAH (vardenafil inhalation powder) for Pulmonary Arterial Hypertension treatment on an as-needed basis, and RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease. All products utilize the AOS DPI device as the delivery mechanism.

Product and service3 records
1RT234-PAH
CategoryInhaled pharmaceutical therapy
Description

First-in-class inhaled therapy (vardenafil inhalation powder) for Pulmonary Arterial Hypertension (PAH), intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue. Delivered via the AOS DPI device. Currently in Phase 2 clinical trials.

2RT234-ILD PH
CategoryInhaled pharmaceutical therapy
Description

Inhaled vardenafil therapy in development for treatment of Pulmonary Hypertension in Interstitial Lung Disease, targeting breathlessness, fatigue, and exercise capacity in ILD patients with elevated pulmonary artery pressures.

3AOS DPI (Axial Oscillating Sphere Dry Powder Inhaler)
CategoryInhaler device technology
Description

Proprietary capsule-based dry powder inhaler device with four distinct dispersion elements designed for efficient pulmonary drug delivery to the lung periphery. Core enabling technology for the RT234 drug-device combination products.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

Gossamer Bio entered into an agreement granting them option to acquire Respira Therapeutics and its inhaled vardenafil product candidate (RT234). This represents a significant strategic transaction for Respira, potentially leading to full acquisition. Gossamer is developing seralutinib for pulmonary hypertension conditions.

Strategic tierCoreTypeOthers
Description

FDA has granted Orphan Drug designation for vardenafil (active ingredient in RT234) for the treatment of Pulmonary Arterial Hypertension. This designation provides incentives including potential market exclusivity and regulatory support.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specializes in aerosol drug delivery technologies for respiratory care, sharing Respira's focus on advanced pulmonary drug delivery device innovation for critical care applications.

TypeDirect peer
Description

Market leader in Pulmonary Arterial Hypertension therapies (Tyvaso, Remodulin, Orenitram), directly competing in the same PAH market that Respira targets with RT234-PAH.

TypeDirect peer
Description

Clinical-stage biopharma developing seralutinib for pulmonary hypertension and has an option to acquire Respira Therapeutics, representing both a peer in PAH drug development and a strategic acquirer.

TypeDirect peer
Description

Clinical-stage company developing inhaled treprostinil (YUTREPIA) for PAH and pulmonary hypertension associated with interstitial lung disease, directly competing with Respira's RT234-ILD PH program.

TypeDirect peer
Description

Develops inhaled drug-device combination products (Afrezza) using proprietary dry-powder inhalation technology, sharing Respira's drug-device inhalation platform focus and clinical-stage biopharma profile.

TypeDirect peer
Description

Specializes in inhaled drug delivery including dry-powder inhaler technology development and licensing, operating a similar business model of developing DPI-based therapies for respiratory diseases.

TypeBroad incumbent
Description

Established biopharma with ARIKAYCE for lung infections and growing pipeline in pulmonary diseases including inhaled therapies, representing a larger incumbent in the inhaled respiratory drug space.

TypeEmerging player
Description

Clinical-stage company developing inhaled therapies for pulmonary diseases using proprietary iSPERSE technology, overlapping with Respira's particle engineering and inhaled drug delivery focus.

TypeEmerging player
Description

Clinical-stage biopharma developing therapeutics including inhaled formulations for cardiopulmonary conditions, sharing Respira's focus on vascular and pulmonary drug delivery.

10Actelion Pharmaceuticals (Johnson & Johnson)
TypeBroad incumbent
Description

Historical PAH market leader (now part of J&J), maker of Tracleer, Opsumit, and Uptravi that established chronic PAH treatment paradigms Respira's PRN approach must differentiate against.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Respira Therapeutics

Inhaled Pulmonary Therapeuticsrespiratherapeutics.com

Respira Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class inhaled vardenafil therapies via its proprietary AOS™ Dry-Powder Inhaler for patients with Pulmonary Arterial Hypertension and ILD-associated Pulmonary Hypertension, currently pre-revenue and subject to a Gossamer Bio acquisition option.

What Respira Therapeutics does

Respira Therapeutics is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Palo Alto, California, developing next-generation inhaled therapies for cardiopulmonary diseases. The company is built around a proprietary drug-device platform combining the AOS™ (Axial Oscillating Sphere) Dry-Powder Inhaler, which uses four distinct dispersion elements to target the lung periphery, with advanced particle engineering formulations. Its lead candidate, RT234-PAH, is a first-in-class reformulation of vardenafil (a potent PDE5 inhibitor) as an inhalation powder intended for "as-needed" (PRN) use in patients with Pulmonary Arterial Hypertension (PAH). The company is also developing RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease (WHO Group 3.2). Respira has received FDA Orphan Drug designation for vardenafil in PAH and is pursuing approval via the 505(b)(2) regulatory pathway.

The company's business model is pre-commercial: Respira generates no product revenue and instead derives value from advancing clinical assets and from strategic partnership and licensing arrangements. As a 1-10 employee venture-backed entity (currently owned by Samsara BioCapital), the company selectively partners with pharmaceutical firms facing unique pulmonary delivery challenges. In September 2025, Respira entered an agreement with Gossamer Bio granting Gossamer an option to acquire the company and its inhaled vardenafil candidate. End-customers are PAH and ILD-PH patient populations (~30,000 each in the U.S.) in an estimated $8B global PAH treatment market; commercialization would route through standard pharmaceutical distribution and specialty pulmonary channels following FDA approval.

Leadership combines deep drug-device commercialization and inhaled delivery expertise, including CEO John Kollins (ex-Satsuma Pharmaceuticals CEO), Chairman William Fairey (former Actelion US President, ex-MyoKardia CCO), and board member Michael Riebe (former VP of Inhalation Product Development at AstraZeneca). Backed by Cottonwood Technology Fund, Sun Mountain Capital, Keiretsu Forum Northwest, and Samsara BioCapital, Respira has raised approximately $5.1M-$6.1M in disclosed equity financing through 2015 and is operating with Phase 2b VIPAH-PRN clinical data presented at ATS 2025 as its most recent substantive milestone.

Respira Therapeutics firmographics

Firmographics
Name
Respira Therapeutics
Legal name
Respira Therapeutics Inc.
Website
https://respiratherapeutics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Respira Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class inhaled vardenafil therapies via its proprietary AOS™ Dry-Powder Inhaler for patients with Pulmonary Arterial Hypertension and ILD-associated Pulmonary Hypertension, currently pre-revenue and subject to a Gossamer Bio acquisition option.
Ownership category
akta.pro rank

Respira Therapeutics industry classification

Industry
Product category
Inhaled Pulmonary Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Inhaled drug delivery
  • Dry powder inhalers
  • Pulmonary hypertension therapy
  • Pharmaceutical drug development
  • Vardenafil inhalation powder

Where Respira Therapeutics is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Respira Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Expected to commercialize RT234-PAH and RT234-ILD PH upon FDA approval. Product is first-in-class inhaled therapy for PAH patients, contrasting with chronic treatment regimens of existing therapies.
  2. Strategic Partnerships and Licensing: Company selectively partners with pharmaceutical companies having unique pulmonary delivery challenges. Agreement with Gossamer Bio grants option to acquire Respira and its inhaled vardenafil product candidate.
  3. Future Product Pipeline: Pipeline includes wholly owned development candidates with anticipation to launch additional product development programs. Focus on 505(b)(2) products that may improve standard of care.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Respira Therapeutics product offering

Product offering

Core offering

Respira Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug-device combination products for cardiopulmonary diseases. Its lead candidate RT234-PAH is a first-in-class inhaled vardenafil dry powder formulation delivered via the proprietary AOS™ Dry-Powder Inhaler (DPI), intended for as-needed (PRN) use in patients with Pulmonary Arterial Hypertension (PAH). The company also develops RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease and pursues 505(b)(2) regulatory pathways.

Product overview

Respira Therapeutics is a clinical-stage biopharmaceutical company developing next-generation cardiopulmonary disease-targeted inhalation products. The company operates a platform combining its proprietary AOS™ dry-powder inhaler (DPI) device with advanced particle engineering-based inhaled drug formulations to enhance drug delivery to the lung periphery. The core product portfolio includes RT234-PAH (vardenafil inhalation powder) for Pulmonary Arterial Hypertension treatment on an as-needed basis, and RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease. All products utilize the AOS DPI device as the delivery mechanism.

Differentiator

Problem solved

Functional benefit

Brands

  • RT234-PAH: First-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue in pulmonary arterial hypertension (PAH) patients.
  • RT234-ILD PH
  • AOS DPI (Axial Oscillating Sphere Dry Powder Inhaler)

Products and services

  • RT234-PAH First-in-class inhaled therapy (vardenafil inhalation powder) for Pulmonary Arterial Hypertension (PAH), intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue. Delivered via the AOS DPI device. Currently in Phase 2 clinical trials.
  • RT234-ILD PH Inhaled vardenafil therapy in development for treatment of Pulmonary Hypertension in Interstitial Lung Disease, targeting breathlessness, fatigue, and exercise capacity in ILD patients with elevated pulmonary artery pressures.
  • AOS DPI (Axial Oscillating Sphere Dry Powder Inhaler) Proprietary capsule-based dry powder inhaler device with four distinct dispersion elements designed for efficient pulmonary drug delivery to the lung periphery. Core enabling technology for the RT234 drug-device combination products.

Quantifiable outcome

  • Phase 2b clinical trial demonstrated acute improvement in exercise capacity and reduced dyspnea in PAH patients
  • +3 more outcomes

Companies that use Respira Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Respira Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Respira Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Gossamer BiocoreStrategic or Co-development Partner · 25 September 2025Gossamer Bio entered into an agreement granting them option to acquire Respira Therapeutics and its inhaled vardenafil product candidate (RT234). This represents a significant strategic transaction for Respira, potentially leading to full acquisition. Gossamer is developing seralutinib for pulmonary hypertension conditions.
  • FDA (Orphan Drug Designation)coreOthersFDA has granted Orphan Drug designation for vardenafil (active ingredient in RT234) for the treatment of Pulmonary Arterial Hypertension. This designation provides incentives including potential market exclusivity and regulatory support.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Respira Therapeutics competitors and assessment

Company assessment

Direct peers

  • Aerogen: Specializes in aerosol drug delivery technologies for respiratory care, sharing Respira's focus on advanced pulmonary drug delivery device innovation for critical care applications.
  • United Therapeutics: Market leader in Pulmonary Arterial Hypertension therapies (Tyvaso, Remodulin, Orenitram), directly competing in the same PAH market that Respira targets with RT234-PAH.
  • Gossamer Bio: Clinical-stage biopharma developing seralutinib for pulmonary hypertension and has an option to acquire Respira Therapeutics, representing both a peer in PAH drug development and a strategic acquirer.
  • Liquidia Technologies: Clinical-stage company developing inhaled treprostinil (YUTREPIA) for PAH and pulmonary hypertension associated with interstitial lung disease, directly competing with Respira's RT234-ILD PH program.
  • MannKind Corporation: Develops inhaled drug-device combination products (Afrezza) using proprietary dry-powder inhalation technology, sharing Respira's drug-device inhalation platform focus and clinical-stage biopharma profile.
  • Vectura Group: Specializes in inhaled drug delivery including dry-powder inhaler technology development and licensing, operating a similar business model of developing DPI-based therapies for respiratory diseases.

Broad incumbents

  • Insmed: Established biopharma with ARIKAYCE for lung infections and growing pipeline in pulmonary diseases including inhaled therapies, representing a larger incumbent in the inhaled respiratory drug space.
  • Actelion Pharmaceuticals (Johnson & Johnson): Historical PAH market leader (now part of J&J), maker of Tracleer, Opsumit, and Uptravi that established chronic PAH treatment paradigms Respira's PRN approach must differentiate against.

Emerging players

  • Pulmatrix: Clinical-stage company developing inhaled therapies for pulmonary diseases using proprietary iSPERSE technology, overlapping with Respira's particle engineering and inhaled drug delivery focus.
  • Phase Bio Pharmaceuticals: Clinical-stage biopharma developing therapeutics including inhaled formulations for cardiopulmonary conditions, sharing Respira's focus on vascular and pulmonary drug delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Respira Therapeutics social profiles

Digital presence

Respira Therapeutics compliance and trust

Trust signal

Compliance1 record

Respira Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Respira Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Respira Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Respira Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Respira Therapeutics

What does Respira Therapeutics do?

Respira Therapeutics is a clinical-stage biopharmaceutical company developing inhaled drug-device combination products for cardiopulmonary diseases. Its lead candidate RT234-PAH is a first-in-class inhaled vardenafil dry powder formulation delivered via the proprietary AOS™ Dry-Powder Inhaler (DPI), intended for as-needed (PRN) use in patients with Pulmonary Arterial Hypertension (PAH). The company also develops RT234-ILD PH for Pulmonary Hypertension associated with Interstitial Lung Disease and pursues 505(b)(2) regulatory pathways.

Is Respira Therapeutics a public or private company?

Respira Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Respira Therapeutics founded?

Respira Therapeutics was founded in 2010. It employs 11 to 50 people.

Where is Respira Therapeutics based?

Respira Therapeutics is headquartered in Palo Alto, United States, in the North America region.

How does Respira Therapeutics make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are strategic Partnerships and Licensing and future Product Pipeline.

Who are Respira Therapeutics's main competitors?

Direct peers on record are Aerogen, United Therapeutics, Gossamer Bio, Liquidia Technologies, MannKind Corporation and Vectura Group. Broad incumbents are Insmed and Actelion Pharmaceuticals (Johnson & Johnson). Emerging players are Pulmatrix and Phase Bio Pharmaceuticals.

Does Respira Therapeutics have an API?

No public API is recorded for Respira Therapeutics.

What industry is Respira Therapeutics in?

Respira Therapeutics's product category is Inhaled Pulmonary Therapeutics. Its primary akta.pro industry code is HLAIAIAI, Rare Renal & Nephrology Disorder Therapies, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsightDelveInsight published a market insights report on the Pulmonary Arterial Hypertension (PAH) treatment market, estimating it at USD 8 billion in 2025 in leading markets (US, EU4, UK, Japan), with projected growth at a CAGR of 6.7% through 2036. United Therapeutics announced in March 2026 that its drug ralinepag achieved a 55% reduction in risk of clinical worsening in a pivotal PAH study, representing a significant clinical milestone. Multiple companies including Gossamer Bio, Liquidia Technologies, Respira Therapeutics, and Insmed are advancing new PAH therapies through clinical development, with several expected to launch in the coming years.Business Wire BlogGossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business UpdateGossamer Bio reported Q3 2025 financial results with cash of $180.2 million, revenue of $13.3 million, and a net loss of $48.2 million, compared to a net loss of $30.8 million in Q3 2024. The company completed enrollment for its PROSERA Phase 3 study with 390 PAH patients and expects topline results in February 2026, while also activating the first clinical site for its SERANATA Phase 3 study in PH-ILD. Gossamer entered into a strategic option agreement to acquire Respira Therapeutics and its inhaled vardenafil candidate, with an option exercise potentially involving the issuance of 1.5 million shares of common stock.PulmonaryhypertensionnewsGossamer gains rights to acquire PH treatment candidate RT234Gossamer Bio has entered into an option agreement with Respira Therapeutics, granting it the exclusive right to acquire Respira and its lead drug candidate RT234 for the treatment of pulmonary hypertension. Under the agreement, Gossamer will fund certain development expenses for up to two years while retaining the flexibility to focus on its own seralutinib project, with plans to pursue U.S. regulatory approval via the 505(b)(2) pathway if the acquisition is completed.PR NewswireRespira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapitalRespira Therapeutics has entered into an agreement with Gossamer Bio granting Gossamer an option to acquire the company. Under the terms, Gossamer is issuing 2.5 million shares of common stock at signing, with an additional 1.5 million shares upon exercise of the acquisition option, plus potential success-based clinical, regulatory, and commercial milestone payments and royalties tied to RT234. During the up-to-two-year option period, Gossamer will fund development activities focused on advancing RT234, an investigational first-in-class as-needed treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Financial TimesGossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension – Company AnnouncementGossamer Bio entered an option agreement to acquire Respira Therapeutics and its lead candidate RT234, an inhaled vardenafil for pulmonary hypertension. The deal involves issuing 2.5 million shares on signing and 1.5 million upon exercise, with milestone payments and royalties. Gossamer plans to pursue a 505(b)(2) pathway and expects clinical trials to start in 2027.LwLatham & Watkins Advises Gossamer Bio in Option Agreement to Acquire Respira TherapeuticsGossamer Bio has entered into an option agreement to acquire Respira Therapeutics and its lead product candidate, RT234. The transaction is being advised by Latham & Watkins LLP on behalf of Gossamer Bio.Daily Medical NewsInhaled formulation of vardenafil for as-needed use shows promise in PAHRespira Therapeutics reported positive phase 2a trial data for RT234, an inhaled formulation of vardenafil designed for as-needed use in patients with pulmonary arterial hypertension. The study demonstrated that the treatment significantly reduced pulmonary vascular resistance and improved exercise capacity while maintaining a favorable safety profile compared to oral alternatives.PR NewswireRespira to Present Clinical Data on RT234-PAH Patient-Controlled Treatment to Acutely Improve Episodic Symptoms in Pulmonary Arterial Hypertension (PAH) PatientsRespira Therapeutics presented clinical data from Phase 1 and Phase 2a studies of its lead product candidate RT234-PAH at the American College of Chest Physicians virtual CHEST Annual Meeting 2020, showing that the inhaled vardenafil treatment demonstrated rapid onset of action with pulmonary vascular resistance reduction within 5 minutes and sustained effect for at least 60 minutes. The trials found RT234 was well tolerated with minimal safety and tolerability issues when used alongside existing PAH maintenance therapies, supporting its development as a first-in-class, as-needed treatment for episodic symptoms in pulmonary arterial hypertension patients. The FDA has granted Orphan Drug designation for the active ingredient, and the company is pursuing the 505(b)(2) approval pathway with RT234 currently in Phase 2 clinical testing.BloombergStartup Seeks Nod for Inhaler to Help Smokers QuitRespira Technologies Inc. plans to submit an inhaler device to the FDA by late 2021 for authorization as nicotine replacement therapy. The nebulizer converts nicotine to an aerosol and aims to disrupt an estimated $618 billion market dominated by gums, patches, and cigarette alternatives.PR NewswireRespira Therapeutics Regains North America Rights from United Therapeutics to Phase 2 Inhaled Drug-Device Product, RT234, for Pulmonary Hypertension IndicationsRespira Therapeutics has regained full worldwide research, development, and licensing rights to its inhaled drug-device product RT234 from United Therapeutics following the conclusion of their collaboration. This strategic decision by United Therapeutics allows Respira to proceed independently with Phase 2 clinical studies for pulmonary arterial hypertension indications without further funding obligations to the partner. The move positions Respira to maximize the value of the RT234 program as a first-in-class as-needed therapy.